Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...